Quest for the right Drug
ג'נואט 50 מ"ג/850 מ"ג JANUET 50 MG/850 MG (METFORMIN HYDROCHLORIDE, SITAGLIPTIN AS MONOHYDRATE PHOSPHATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosing The dosage of JANUET should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the health care provider. JANUET should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to metformin. JANUET must not be split or divided before swallowing. The starting dose of JANUET should be based on the patient’s current regimen. JANUET should be given twice daily with meals. The following doses are available: 50 mg sitagliptin/500 mg metformin hydrochloride 50 mg sitagliptin/850 mg metformin hydrochloride 50 mg sitagliptin/1000 mg metformin hydrochloride. The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. Patients treated with an insulin secretagogue or insulin Coadministration of JANUET with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.9)]. No studies have been performed specifically examining the safety and efficacy of JANUET in patients previously treated with other oral antihyperglycemic agents and switched to JANUET. Any change in 1 therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
רישום
139 90 31902 11
מחיר
0 ₪
מידע נוסף